Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.
The battle lines were drawn between those who recognize the corrosive effect that the pharmaceutical industry is having on the safety and integrity of medicine and medical research, and the powerful stakeholders–the pharmaceutical-academic industrial complex.
Urge your Senators to VOTE YES for the Child Medication Safety Act (S. 4041, HR 1790) !!!
Two especially timely conferences focus on MEDICINE AND THE LAW:
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
The most striking acknowledgement in this sad story underscores the shaky foundation upon which the field of child psychiatry rests is the following statement by a Harvard University child psychiatrist: "When she was almost 8… Haley met full criteria for virtually every mental disorder listed."
Alternative Medicine is a national magazine with 165,000 subscribers. It is also sold nationwide on newsstands. Its cover story, Nov/Dec, is Kids & Psychiatric Drugs: BIG PHARMA comes to the classroom!
No legitimate physician would use the physician’s professional license to help repressive government regimes intimidate dissidents.
FDA issued an advisory stating that the concealed study results demonstrate "that use of Trasylol may increase the chance for death, serious kidney damage, congestive heart failure and strokes."
Dr. Sanghavi provides us with a statistical reality-check by which to gauge for ourselves whether or not we should–or need not–take a octor’s advice about starting a medical treatment for a speculated risk–rather than evidence of illness.
“The Drug Trial That Went Wrong” is an investigative report by Chanel 4 (UK) about the circumstances surrounding the near fatal drug trial testing the safety of TGN1412, a monoclonal antibody drug, conducted in March 2006 at London’s Northwick Park Hospital. [1] http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/5377226.stm It airs momorrow.
"As long as we continue to manipulate biology in new ways, we probably cannot prevent all such events from occurring. We must do what we can to minimize risk, but the future health of the world population demands that we not let adverse events put an end to medical progress."
